A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ IN HEALTHY PARTICIPANTS
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs PF 6651600 (Primary) ; Efavirenz; Midazolam
- Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
- 25 Mar 2019 Status changed from active, no longer recruiting to completed.
- 18 Feb 2019 Planned End Date changed from 4 Apr 2019 to 21 Feb 2019.
- 18 Feb 2019 Status changed from recruiting to active, no longer recruiting.